Rheumatology: Current Research
Open Access

Clinic of Internal Medicine III, Department of Internal Medicine III with Haematology, Medical Oncol, Paracelsus Medical University, Salzburg, Austria, Cancer Cluster Salzburg, Austria

Biography

Dr Richard Greil currently works at the University Clinic of Internal Medicine III, Paracelsus Medical University Salzburg/Uniklinikum. He is Head of the Department and Head of the Laboratory of Immunological and Molecular Cancer Research (LIMCR) as well as of the Center for Clinical Cancer and immunology Trials (CCCIT) at the Salzburg Cancer Research Institute (SCRI). In addition, he is Head of the Cancer Cluster Salzburg (CCS) and chairman of the AGMT (Austrian Group of Medical Tumor Therapy).

Publications

• Case Report   
  Good Response of Lupus Hepatitis to Mycophenolate Mofetil and Belimumab as of Lupus Exanthema to Rituximab: A Case Report
  Author(s): Psenak O*, Studnicka-Benke A, Haufe H and Greil R
  
  A 66-year-old male patient had been primarily treated for cutaneous lupus erythematosus 15 years ago. He received local corticosteroids and following systemic immunosuppressants: methylprednisolone (MP), chloroquine (removed due to retinal haemorrhage), cyclosporine A and azathioprine (both removed due to non-response). Due to polyarthralgia methotrexate as well as golimumab were started. Despite good response, both drugs had to be stopped due to development of hepatitis confirmed by liver biopsy (virus serological tests were negative). Early after onset of a combination treatment with 1 g mycophenolate mofetil (MMF) per day orally and 10 mg/kg belimumab intravenously at weeks 0, 2, 4, followed by every 4 weeks, a marked decrease in liver enzymes could be detected. Due to insufficient response of lupus exanthema, hydroxychloroquine (HCQ) was added. After 9 months o.. View More»
  DOI: 10.35248/2161-1149.19.9.247

  Abstract HTML PDF